Study ID: GOG 3015 YO39523 OVP1601 IMagyn050 GOG Foundation Genentech Hoffmann LaRoche
A PHASE III, MULTICENTER, RANDOMIZED,STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
This study researches the effects of your standard cancer treatment plus either atezolizumab or placebo (an inactive substance that looks like atezolizumab) on OC/FTC/PPC. The study is conducted worldwide with half the patients assigned to get the atezolizumab and the other half assigned to get the placebo; however, because of this research, no one will know who is getting atezolizumab or placebo until the study ends. Patients entering this study can either have their cancer surgery before starting the study, or they can receive treatment first, before getting their cancer surgery partway through the study. Typically, the treatment will last about 66-70 weeks or until your cancer gets worse.
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Maria Bell, MD
Ovary/Fallopian Tube/Primary Peritoneal
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.